These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 34687956)

  • 1. Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: a systematic review.
    Jeremic D; Jiménez-Díaz L; Navarro-López JD
    Ageing Res Rev; 2021 Dec; 72():101496. PubMed ID: 34687956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
    Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
    Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical Appraisal of Amyloid Lowering Agents in AD.
    Decourt B; Boumelhem F; Pope ED; Shi J; Mari Z; Sabbagh MN
    Curr Neurol Neurosci Rep; 2021 Jun; 21(8):39. PubMed ID: 34110536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns.
    Lu D; Dou F; Gao J
    Drug Discov Ther; 2023; 17(6):440-444. PubMed ID: 38220210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel strategies for the fight of Alzheimer's disease targeting amyloid-β protein.
    Xie Y; Wang Y; Jiang S; Xiang X; Wang J; Ning L
    J Drug Target; 2022 Mar; 30(3):259-268. PubMed ID: 34435898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer's Disease.
    Uddin MS; Kabir MT; Rahman MS; Behl T; Jeandet P; Ashraf GM; Najda A; Bin-Jumah MN; El-Seedi HR; Abdel-Daim MM
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Anti-Amyloid-β Therapy for Alzheimer's Disease Treatment: From Clinical Research to Nanomedicine.
    Zhao Z; Liu Y; Ruan S; Hu Y
    Int J Nanomedicine; 2023; 18():7825-7845. PubMed ID: 38144511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer's Disease.
    Krafft GA; Jerecic J; Siemers E; Cline EN
    Front Neurosci; 2022; 16():848215. PubMed ID: 35557606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.
    Lemere CA
    Prog Brain Res; 2009; 175():83-93. PubMed ID: 19660650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in aptamers against Aβ and applications in Aβ detection and regulation for Alzheimer's disease.
    Zheng Y; Zhang L; Zhao J; Li L; Wang M; Gao P; Wang Q; Zhang X; Wang W
    Theranostics; 2022; 12(5):2095-2114. PubMed ID: 35265201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle.
    Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S
    Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond.
    Song C; Shi J; Zhang P; Zhang Y; Xu J; Zhao L; Zhang R; Wang H; Chen H
    Transl Neurodegener; 2022 Mar; 11(1):18. PubMed ID: 35300725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What works and what does not work in Alzheimer's disease? From interventions on risk factors to anti-amyloid trials.
    Bullain S; Doody R
    J Neurochem; 2020 Sep; 155(2):120-136. PubMed ID: 32277473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer's disease-like pathology.
    Gnoth K; Piechotta A; Kleinschmidt M; Konrath S; Schenk M; Taudte N; Ramsbeck D; Rieckmann V; Geissler S; Eichentopf R; Barendrecht S; Hartlage-Rübsamen M; Demuth HU; Roßner S; Cynis H; Rahfeld JU; Schilling S
    Alzheimers Res Ther; 2020 Nov; 12(1):149. PubMed ID: 33189132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease.
    Jongbloed W; Bruggink KA; Kester MI; Visser PJ; Scheltens P; Blankenstein MA; Verbeek MM; Teunissen CE; Veerhuis R
    J Alzheimers Dis; 2015; 45(1):35-43. PubMed ID: 25547634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
    Pinheiro L; Faustino C
    Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease.
    Behl T; Kaur I; Fratila O; Brata R; Bungau S
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Alzheimer's Disease: Beyond Symptomatic Therapies.
    Buccellato FR; D'Anca M; Tartaglia GM; Del Fabbro M; Scarpini E; Galimberti D
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.